CHINYA MURALI: Open Payments
NPI 1831156868 · SAINT PETERS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,911 in 114 payments from 15 companies in 2025. Trend: 2023 $1,599 · 2024 $1,613 · 2025 $1,911
Food & beverage: $1,807Education: $104
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 25 | $391 |
| E.R. Squibb & Sons, L.L.C. | 17 | $358 |
| Otsuka America Pharmaceutical, Inc. | 20 | $329 |
| Neurocrine BioSciences, Inc. | 10 | $172 |
| ABBVIE INC. | 11 | $135 |
| Teva Pharmaceuticals USA, Inc. | 6 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $83 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $69 |
| Supernus Pharmaceuticals, Inc. | 3 | $50 |
| Alkermes, Inc. | 3 | $49 |
Products named: FANAPT, COBENFY, REXULTI, INGREZZA, VRAYLAR, TRINTELLIX, CAPLYTA, AUSTEDO XR.
Industry payments across MO — which companies pay providers there.
